Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3.
STORM Therapeutics is a clinical stage biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.
This is a significant milestone for the RNA enzyme field, as it will establish if this new area of RNA biology is tractable for therapeutic intervention.
